Home /
Europe approves guselkumab (TREMFYA) for children with plaque psoriasis The European Medicines Agency approves guselkumab ( TREMFYA ) to treat plaque psoriasis in children.
Published 4h · 1 source Notable
The fact This treatment targets patients aged 6 to 17 unresponsive to existing therapies.
A major breakthrough for pediatric management of this chronic disease.
🔗 Click the link to read an article on the topic:
Why it matters Cette approbation marque une étape clé dans le traitement du psoriasis pédiatrique, une maladie souvent sous-estimée et difficile à gérer chez les jeunes patients.
What if you saw the whole news differently? Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page. → Auto-synthesis from 1 media source · identified on July 31, 2026